Want to see CYTOF full AI Analyst Report?
Altamira Therapeutics (CYTOF) AI Stock Analysis
Altamira Therapeutics
(Other OTC:CYTOF)
Altamira Therapeutics exhibits significant financial and operational challenges, typical of early-stage biotechnology firms, with notable weaknesses in revenue generation and cash flow management. Technical indicators denote a strong bearish trend, with the stock trading well below key moving averages and showing oversold conditions. The lack of valuation metrics and earnings call insights adds to the uncertainty, leading to a cautious and low overall stock score.
Altamira Therapeutics (CYTOF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $404.65K
- Dividend Yield
- ―
- Average Volume (3M)
- 6,949
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.91
- Revenue Growth
- ―
- EPS Growth
- 81.53%
- Country
- US
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Altamira Therapeutics Business Overview & Revenue Model
Company Description
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo a...
How the Company Makes Money
Altamira Therapeutics primarily generates revenue through the development and commercialization of its RNA-based therapeutic products. The company may earn income from licensing agreements, partnerships, and collaborations with other pharmaceutical c...
Altamira Therapeutics Earnings Call Summary
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Altamira Therapeutics' full-year 2024 financial results and business update call, the company provided several key metrics and strategic insights. The operating loss from continuing operations increased slightly from $6.6 million in 2023 to $6.9 million in 2024. Research and development expenses rose to $3.7 million from $3.4 million the previous year, whereas general and administrative expenses decreased to $3.2 million from $3.5 million. Notably, net finance expenses dropped significantly from $1.5 million to $0.8 million. The net loss for 2024 was reported at $8.5 million, with a cash usage reduction in operations from $12.8 million in 2023 to $6.1 million in 2024. Cash and cash equivalents increased to $1 million by year-end. The company anticipates a reduction in operating expenses following the partial spin-off of its RNA delivery subsidiary, ATAG, and seeks to fund future operations through existing cash, private equity, and strategic partnerships.
Altamira Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTOF, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 26.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYTOF.
Altamira Therapeutics Risk Analysis
Altamira Therapeutics disclosed 41 risk factors in its most recent earnings report. Altamira Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksAltamira Therapeutics Peers Comparison
Overall Rating
JSPR48Neutral
MRKR47Neutral
CELU44Neutral
MBIO43Neutral
GTBP42Neutral- CYTOF25Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JSPR | 48Neutral | $17.31M | -0.33 | -618.87% | ― | ― | 73.74% |
| MRKR | 47Neutral | $16.34M | -2.04 | -56.96% | ― | -56.64% | 64.88% |
| CELU | 44Neutral | $25.96M | -0.45 | 142.25% | ― | -58.14% | 47.25% |
| MBIO | 43Neutral | $3.03M | -0.89 | -34.23% | ― | ― | 85.52% |
| GTBP | 42Neutral | $10.96M | -0.05 | -443.08% | ― | ― | 75.09% |
| CYTOF | 25Underperform | $404.65K | -0.13 | ― | ― | ― | 81.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CYTOF | Altamira Therapeutics Ltd. | 0.07 | -0.02 | -22.22% | |
| GTBP | Gt Biopharma, Inc. | 5.32 | -10.26 | -65.85% | |
| MRKR | Marker Therapeutics | 0.98 | 0.02 | 2.19% | |
| MBIO | Mustang Bio | 0.40 | -0.99 | -71.22% | |
| CELU | Celularity Inc. | 0.80 | -0.92 | -53.49% | |
| JSPR | Jasper Therapeutics, Inc. | 0.52 | -1.58 | -75.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 02, 2025